Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Clinical Therapeutics

• Publication date

  1997-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0149-2918(97)80110-5PMID 9152561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

  1998cited by this paper
• A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV Infection

  1998cited by this paper
• Ritonavir and renal failure.

  1997cited by this paper
• Indinavir nephropathy.

  1997cited by this paper
• A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)

  1996cited by this paper
• Renal failure after treatment with ritonavir.

  1996cited by this paper
• Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

  1996cited by this paper
• Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

  1996cited by this paper
• Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.

  1996cited by this paper
• Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

  1996cited by this paper
• Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

  1996cited by this paper
• Protease inhibitors fly through FDA.

  1996cited by this paper
• In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.

  1996cited by this paper
• Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.

  1996cited by this paper
• Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

  1996cited by this paper
• Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.

  1996cited by this paper
• Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir.

  1996cited by this paper
• Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

  1996cited by this paper
• Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

  1996cited by this paper
• Absence of interaction between Indinavir and Fluconazole, a pharmacokinetic study in HIV patients

  1996cited by this paper
• Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel

  1996cited by this paper
• The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients

  1996cited by this paper
• A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

  1995cited by this paper
• A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.

  1995cited by this paper
• In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

  1995cited by this paper
• Safety and activity of saquinavir in HIV infection.

  1995cited by this paper
• HIV drug resistance.

  1992cited by this paper
• HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

  1989cited by this paper

• Pyrene‐Conjugated, 2‐Pyridinecarboxaldehyde Derivatives as N‐Terminus‐Specific Tags for MALDI‐ and LALDI‐MS

  2026cites this paper
• Rational design, synthesis, and evaluating primary biological activities of novel HIV-1 protease inhibitors containing heteraryl acetamides as the P2 ligands.

  2025cites this paper
• HIV nucleoside reverse transcriptase inhibitors.

  2022cites this paper
• Feline İnfeksiyöz Peritonitise Genel Bakış ve Antiviral Yaklaşımlar

  2021cites this paper
• Repurposing of Antiviral Drugs for Covid-19 Therapy

  2020cites this paper
• Phytotherapeutic Evidence Against Coronaviruses and Prospects for COVID-19

  2020cites this paper
• Improving and validating data-driven genotypic interpretation systems for the selection of antiretroviral therapies

  2016cites this paper
• Tin Selenide Quantum Dots Electrochemical Biotransducer for the Determination of Indinavir - A Protease Inhibitor Anti-Retroviral Drug

  2016cites this paper
• Infections of the Posterior Segment: Cytomegalovirus Retinitis

  2014cites this paper
• Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors

  2013cites this paper
• Exploiting the properties of biomolecules for brain targeting of nanoparticulate systems.

  2012cites this paper
• Usefulness of proviral DNA of human immunodeficiency virus type 1 in AIDS treatment decisions

  2012cites this paper
• Pediatric antiretroviral therapy

  2010cites this paper
• HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces

  2010cites this paper
• Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus

  2010cites this paper
• PEDIATRIC ANTIRETROVIRAL DRUG INFORMATION OVERVIEW: PEDIATRIC ANTIRETROVIRAL DRUGS

  2008influential citation
• HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice.

  2006cites this paper
• Cytomegalovirus Retinitis

  2006cites this paper
• LC-MS/MS determination of the HIV-1 protease inhibitor indinavir in brain and testis of mice.

  2006cites this paper
• Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors

  2005influential citation
• Investigation of oral bioavailability and brain distribution of the Ind(8)‐Val conjugate of indinavir in rodents

  2005cites this paper
• Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 Mice

  2005cites this paper
• Iatrogenic risk factors for cytomegalovirus retinitis.

  2005cites this paper
• A depressão e a adesão ao tratamento da infecção pelo HIV (vírus da imunodeficiência humana)

  2005cites this paper
• Synthèse racémique et énantiosélective d’énol-lactones et leur évaluation comme inhibiteurs de la protéase du VIH-1

  2005cites this paper
• Tecnologia de obtenção de solução oral e cápsulas moles a base de Ritonavir

  2004cites this paper
• HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

  2004cites this paper
• Clinical risk factors for cytomegalovirus retinitis in patients with AIDS.

  2004cites this paper
• Laboratory-based risk factors for cytomegalovirus retinitis.

  2004cites this paper
• Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review.

  2003cites this paper
• MEDICATION ADHERENCE IN HIV POPULATION

  2001cites this paper
• The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.

  2001cites this paper
• PREDICTORS OF PATIENT REPORTED MEDICATION ADHERENCE TO ANTIRETROVIRAL THERAPY

  2001cites this paper
• A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus-Infected Patients Enrolled in a Phase III Clinical Trial

  2000cites this paper
• Conduite à tenir devant une diarrhée chronique chez un malade VIH+

  2000cites this paper
• Assessment and psychotherapy practice implications of new combination antiviral therapies for HIV disease.

  1999cites this paper
• Assisting persons living with HIV/AIDS to return to work: programmatic steps for AIDS service organizations.

  1999cites this paper
• Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection.

  1999cites this paper
• Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.

  1999cites this paper
• Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor

  1999cites this paper
• THE APPLICATION OF THE POPULATION APPROACH TO PHARMACOKINETICS IN DRUG DEVELOPMENT.

  1999cites this paper
• [Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients].

  1999cites this paper
• Drug Interactions of HIV Protease Inhibitors

  1999cites this paper
• Antiretroviral therapy in primary HIV.

  1999cites this paper
• Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.

  1998cites this paper
• Management of HIV-1 Infection in Children

  1998cites this paper
• Criminalization of perinatal HIV transmission.

  1998cites this paper
• Management of HIV-1 Infection in ChildrenConsiderations

  1998cites this paper
• Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors.

  1998cites this paper
• Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection.

  1998cites this paper
• Antiretroviral Therapy and Medical Management of Pediatric HIV Infection

  1998cites this paper
• Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS.

  1998cites this paper
• Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1.

  1997cites this paper